EBS - Emergent begins dosing in phase 1 trial of intranasal therapy for cyanide poisoning

Emergent BioSolutions (NYSE:EBS) dosed the first person in a phase 1 trial of stabilized isoamyl nitrite (SIAN) to treat known or suspected acute cyanide poisoning. Under an existing multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), and in collaboration with the Southwest Research Institute, Emergent is developing a single-use intranasal spray intended for administration by first responders following a cyanide incident. The trial plans to enroll 70 healthy males or non-pregnant females between the ages of 18 to 45. The study is funded by BARDA, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.

For further details see:

Emergent begins dosing in phase 1 trial of intranasal therapy for cyanide poisoning